ReviewCurrent treatment options in oncology2023
Frontiers of Ovarian Carcinosarcoma.
Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 21 citations in OpenAlex.
- Carcinosarcoma of the Ovary Arising in the Background of a Mucinous Neoplasm Distinct From a Mural Nodule.Cureus · 2026Article
- Clinical Features of Malignant Ovarian Germ Cell Tumors According to Demographic and Pathologic Characteristics.Health science reports · 2026Article
- MRI Findings of Ovarian Carcinosarcoma: A Retrospective Comparison With Endometrioid Carcinoma.Cureus · 2026Article
- Endometriosis-Associated Ovarian Carcinosarcoma Featuring Well-Differentiated Adenocarcinoma and Fetal Rhabdomyoma-Like Mesenchymal Components: An Unusual Case Report-With Molecular Analysis.Case reports in pathology · 2026Article
- Sustained disease control in ovarian carcinosarcoma treated with postoperative hyperthermic intraperitoneal chemotherapy and targeted maintenance: a case report.Frontiers in medicine · 2026Article
- The development of ovarian carcinosarcoma from serous tubal intraepithelial carcinoma: an immunohistochemical case report with literature review.Frontiers in oncology · 2026Article
- MEF2C induces intrinsic apoptosis and reverses cisplatin resistance in A2780 ovarian cancer cell line.BMC cancer · 2025Article
- The use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case series.Gynecologic oncology reports · 2025Article
- Dissecting the histological heterogeneity of ovarian carcinosarcoma and high-grade serous ovarian cancer in primary and metastatic tumors by single-cell transcriptomic analysis.Chinese medical journal · 2025Article
- Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report.Diseases (Basel, Switzerland) · 2025Review
- Stage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission.Frontiers in oncology · 2025Article
- Teratoma combined with struma ovarii and sarcomatoid carcinoma: a case report and review of the literature.BMC women's health · 2024Review
- A Case of Carcinosarcoma of the Peritoneum With Serous Tubal Intraepithelial Carcinoma.Case reports in obstetrics and gynecology · 2024Article
- Malignant mixed mullerian tumors: a SEER database review of rurality and treatment modalities on disease outcome.Frontiers in oncology · 2024Article
- Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids.Frontiers in oncology · 2024Article
- Recurrent mucinous carcinoma with sarcomatoid and sarcomatous mural nodules: a case report and literature review.Frontiers in oncology · 2024Article
- Ovarian carcinosarcomas: p53 status defines two distinct patterns of oncogenesis and outcomes.Frontiers in oncology · 2024Article
- Clinicopathological and molecular features of tubo-ovarian carcinosarcomas: a series of 51 cases.Frontiers in oncology · 2024Article
- Tumor Markers in Differential Diagnosis of Benign Ovarian Masses.International journal of women's health · 2024Article
- Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementOvarian carcinosarcoma (OCS), also known as a malignant mixed Müllerian tumour (MMMT), is a rare and aggressive form of cancer that accounts for less than 5% of ovarian cancers. It is characterized by high morbidity and mortality rates, with a median overall survival (OS) of less than 2 years. Several factors, including advancing age, nulliparity, reduced lactation rates, decreased use of oral contraceptive pills, genetic mutations in BRCA (breast cancer) genes, and the use of assisted reproductive technology, may increase the risk of OCS. Poor prognostic factors include an advanced stage at diagnosis, older age, lymph node metastasis, suboptimal surgical cytoreduction, the presence of heterologous features on histopathology, and increased expression of vascular endothelial growth factor (VEGF), tumour protein p53, and p53 alongside Wilms tumour 1 (WT1). The main treatment approach for OCS is cytoreductive surgery followed by platinum-based chemotherapy, although immunotherapy is showing promise. Homologous recombination deficiency (HRD) testing may enhance outcomes by enabling personalized immunotherapy and targeted therapies for specific patient groups, thereby reducing unnecessary side effects and healthcare costs. However, there is currently a lack of standardised treatment regimens for OCS patients, with most studies consisting of case reports and a shortage of suitable comparator groups. This article aims to provide clinicians with information on the epidemiology, risk factors, prognostic factors, and latest therapeutic advancements in OCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.